Thermo Fisher Scientific Inc., the world leader in serving science, announced the global launch of the Gibco™ CTS™ Compleo™ Fill ...
Lilly to gain ownership of Centessa's OX2R agonist pipeline designed to improve outcomes across sleep-wake disorders Centessa’s OX2R agonist pip...
Final participant randomized in the GenePHIT Phase 2 clinical trial assessing safety and efficacy of AB-1002 for adults with non-ischemic cardiomyopath...
Adds 60,000 liters of drug substance capacity, bringing the total to 845,000 liters Marks Samsung Biologics’ geographical diversific...
New collaboration structure achieves meaningfully improved financial terms and flexibility for Galapagos Following this transaction, the Company w...
Enrollment underway in second Avacta clinical program at first three specialist U.S. oncology centers Initial data from the trial expected later this ye...
Acquisition will bring two differentiated commercialized immunology medicines to Biogen with EMPAVELI® FDA-approved in three indications, including...
COVALENT-211 Phase II enrolling insulin-deficient type 2 diabetes patients COVALENT-212 Phase II enrolling type 2 diabetes patients uncontrolled wit...
Enables expression of active GPCRs in 48 hours Panel supports screening to scale-up on eProtein Discovery Nuclera, the biotechnology comp...
Expands Otsuka portfolio in psychiatric and neurological fields and aims to accelerate development of Transcend's portfolio, including the TSND-201 progr...
Stratum Biosciences, a biotechnology pioneer at the intersection of artificial intelligence and dermatology research, announced the closing of a $2...
Mayo Clinic announces a gift of $75 million from the Thomas and Elizabeth Grainger family to support Bold. Forward. Unbound. in Rochester, Mayo Clinic's ...
Eli Lilly and Company announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekiz...
Acquisition brings together Excellergy's differentiated trifunctional allergic effector cell response inhibitors (ECRIs) and the development expertise o...
© 2026 Biopharma Boardroom. All Rights Reserved.
